Search

Search Constraints

You searched for: Author/Creator Novak, Gerald P.

Search Results

1. [P4–014]: THE COALITION AGAINST MAJOR DISEASES: TOWARD U.S. FDA QUALIFICATION OF HIPPOCAMPAL VOLUME AS A BIOMARKER FOR ENRICHMENT IN CLINICAL TRIALS FOR PRE‐DEMENTIA STAGES OF ALZHEIMER'S DISEASE. (1st July 2017)

3. [P4–341]: LEVELS OF BLOOD PRESSURE, BODY MASS INDEX AND TOTAL SERUM CHOLESTEROL AT DIFFERENT TIME POINTS PRIOR TO DEMENTIA DIAGNOSIS: A CASE CONTROL STUDY OF OVER 28 MILLION ELECTRONIC HEALTH RECORDS FROM THE EMIF EHR DATA RESOURCE. (1st July 2017)

4. Association of late‐onset dementia risk scores and Alzheimer's disease pathology status in preclinical older adults: Neuropsychiatry and behavioral neurology: Novel risk factors and novel approaches to risk in dementia. (7th December 2020)

5. Effect‐modifying role of education and crystalized intelligence on the association of amyloid pathology and cognitive function: Neuropsychiatry and behavioral neurology/presymptomatic disease/prodromal disease/prodromal states. (7th December 2020)

6. F1‐02‐03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF‐AD BIOMARKER DISCOVERY STUDY. (1st July 2006)

7. FTS3‐01‐04: FINAL EFFICACY, SAFETY AND BIOMARKER RESULTS OF THE PHASE 2B/3 RANDOMIZED, DOUBLE‐BLINDED, PLACEBO‐CONTROLLED EARLY TRIAL OF ATABECESTAT IN PRECLINICAL ALZHEIMER'S DISEASE. (1st July 2019)

9. O4‐04‐04: Pooled biomarker analyses of phase 2 studies of vanutide cridificar vaccine (ACC‐001) in mild‐to‐moderate and early Alzheimer's disease. (1st July 2015)

10. P1‐155: The path to regulatory qualification of low baseline hippocampal volume as a prognostic biomarker in clinical trials of patients with early Alzheimer's disease: For the coalition against major diseases. (1st July 2015)